Logo

AbbVie's Humira (adalimumab) Receives Health Canada Approval for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients

Share this

AbbVie's Humira (adalimumab) Receives Health Canada Approval for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients

Shots:

  • The approval is based on SYCAMORE study assessing Humira (20mg- 40 mg- based on body wt.) + methotrexate vs methotrexate + PBO in 114 patients in a ratio (2:1) with active JIA-associated noninfectious anterior uveitis refractory to at least 12 weeks of methotrexate treatment aged > 2yrs.
  • The SYCAMORE study resulted in meeting 1EPs- with delayed treatment failure (27% vs 60%)
  • Humira (adalimumab- SC- q2w) is a mab blocking TNF-a protein targeted for an inflammatory response of immune-mediated diseases and is approved in 90 countries for 15 indications

Ref: PRNewswire | Image: AbbVie

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions